Adding the pan-AKT inhibitor capivasertib to first-line paclitaxel in metastatic triple-negative breast cancer (TNBC) led to significantly longer progression-free survival (PFS) and overall survival (OS) versus placebo–paclitaxel in the phase II PAKT trial. CAPItello-290 was designed to further assess capivasertib–paclitaxel, including in patients with PIK3CA/AKT1/PTEN-altered tumours.
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
Annals of Oncology | | P.S. Schmid, H.L. McArthur, J. Cortés, B. Xu, F. Cardoso, M. Casalnuovo, U. Demirci, R. Freitas-Junior, J. Ghosh, R. Hegg, H. Iwata, I. Karnaukhov, Y.L. Chuken, M. Nechaeva, M.E. Robson, R. Villalobos-Valencia, T. Yamashita, B. Zurawski, E.C. de Bruin, L. Grinsted, C. D’Cruz, A. Foxley, Y.H. Park
Topics: breast-cancer, blood-cancer, chemotherapy, clinical-trials